Skip to main content

Table 3 Most common (>20%) non-serious adverse events

From: A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

Adverse event Number of patients and percentage
Stomatitis 12, 80%
Proteinuria 11, 73.3%
White blood cell count decrease 8, 53.3%
Hyperglycaemia 7, 46.7%
Pyrexia 6, 40%
Gamma-glutamyltransferase increased 6, 40%
Anemia 5, 33.3%
Platelet count decrease 5, 33.3%
Hypoalbuminaemia 5, 33.3%
Blood cholesterol increased 5, 33.3%
Fatigue 4, 26.7%
Blood alkaline phosphatase increased 4, 26.7%
ALT increase 3, 20%
Interstitial lung disease 3, 20%